New hope for rare blood disorder: crovalimab trial shows promise in controlling PNH
NCT ID NCT04654468
First seen Nov 17, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study tests a new drug, crovalimab, in about 50 people with a rare blood disease called PNH. The goal is to see if the drug can control the destruction of red blood cells and reduce the need for blood transfusions. Participants receive crovalimab for at least 24 weeks, and the study measures how well the drug works and its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, 300020, China
-
Tianjin Medical University General Hospital
Tianjin, 300052, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
Conditions
Explore the condition pages connected to this study.